Keros Therapeutics Inc (KROS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.25 Million) by net assets ($703.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Keros Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Keros Therapeutics Inc for a breakdown of total debt and financial obligations.
Keros Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Keros Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harbin Air Conditioning Co Ltd
SHG:600202
|
0.049x |
|
ZheJiang BangJie Digital Knitting Share Co Ltd
SHE:002634
|
-0.009x |
|
Wuhan Citms Technology Co Ltd
SHG:688038
|
-0.054x |
|
CMC Magnetics Corp
TW:2323
|
-0.033x |
|
Shenzhen Maxonic Auto Control
SHE:300112
|
0.015x |
|
Shenzhen L&A Design Holding Limited
SHE:300949
|
N/A |
|
Pioneer Bancorp Inc
NASDAQ:PBFS
|
0.012x |
|
GSR III Acquisition Corp. Ordinary Shares
NASDAQ:GSRT
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Keros Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Keros Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Keros Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $571.55 Million | $-160.87 Million | -0.281x | +24.90% |
| 2023-12-31 | $332.21 Million | $-124.51 Million | -0.375x | -48.40% |
| 2022-12-31 | $277.42 Million | $-70.06 Million | -0.253x | +1.18% |
| 2021-12-31 | $243.17 Million | $-62.15 Million | -0.256x | -81.30% |
| 2020-12-31 | $261.72 Million | $-36.89 Million | -0.141x | +95.20% |
| 2019-12-31 | $5.45 Million | $-16.00 Million | -2.935x | -631.71% |
| 2018-12-31 | $12.76 Million | $7.04 Million | 0.552x | -- |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more